–Strengthens leadership team to support
continued advancement of novel therapeutics for rare and serious
endocrine diseases–
Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage
biopharmaceutical company primarily focused on developing novel
treatments for orphan endocrine diseases with significant unmet
needs, announced today the appointments of Tamara Joseph, JD, LLM,
as General Counsel and Corporate Secretary and Ryan Zeidan, PhD, as
Chief Development Officer. Ms. Joseph succeeds Jeffery M. Brinza
who announced his retirement in March.
"We are pleased to welcome Tamara to our company and executive
leadership team," said Julia C. Owens, PhD, President and Chief
Executive Officer of Millendo Therapeutics. "As we continue to
advance our portfolio of novel endocrine therapeutics, Tamara’s
broad experience across public companies and the global
biopharmaceutical industry, particularly in rare diseases, makes
her an ideal addition to the Millendo team. We thank Jeff for his
four years of service to the company and wish him well in his
retirement.
“I am also excited to announce Ryan’s promotion to Chief
Development Officer, recognizing the significant impact he has made
since joining our company last year. Tamara and Ryan’s deep
expertise and leadership will be critical to Millendo as we
continue to build our development and commercial capabilities,” Dr.
Owens added.
The company is currently conducting a pivotal Phase 2b/3
clinical study for its lead program, livoletide for the treatment
of Prader-Willi syndrome, and a Phase 2b study of nevanimibe for
the treatment of classic congenital adrenal hyperplasia. MLE-301, a
preclinical asset for the treatment of vasomotor symptoms
associated with menopause, is advancing toward the clinic.
“I was drawn to Millendo for its promising science, talented
team, notable progress to date and the opportunity to bring
therapies to patients suffering from serious endocrine diseases,”
said Ms. Joseph. “I am thrilled to be joining Millendo at this
exciting point in its lifecycle, and I look forward to working with
Julia, Ryan and the entire team.”
Ms. Joseph joins Millendo with more than 20 years of leadership
roles in multiple biotechnology companies, overseeing legal,
compliance, public and government affairs, and risk management. She
most recently served as General Counsel at Enzyvant Therapeutics
and previously served as General Counsel at InVivo Therapeutics,
Cubist Pharmaceuticals, Mayne Pharma, and Transkaryotic Therapies
(TKT). She led Mayne Pharma’s team and advised its Board of
Directors during the company’s acquisition by Hospira and advised
TKT’s Board on that company’s acquisition by Shire. She also
established and led the ex-US operations of the Biogen Idec legal
and public affairs departments. Ms. Joseph received her bachelor’s
degree in economics from Duke University, her JD from the
University of Michigan Law School and her LLM degrees from the
College of Europe in Belgium and the University of Paris.
Dr. Zeidan has served as Senior Vice President of Development at
Millendo since joining the company in 2018. In this role he has
overseen critical R&D functions including clinical operations,
project management, CMC and regulatory affairs. Prior to Millendo,
Dr. Zeidan was with Celgene, where he oversaw the development and
advancement of two late-stage oncology assets to Phase 3
registration studies, and with Novartis Oncology, where he served
as Executive Director, Global Strategy and Operations. Earlier, he
worked at the Boston Consulting Group and Calando Pharmaceuticals.
Dr. Zeidan holds a Ph.D. in chemistry and chemical engineering from
the California Institute of Technology, and bachelor’s degrees in
chemistry and chemical engineering from the Massachusetts Institute
of Technology.
Inducement Equity Awards
On August 19, 2019, the Compensation Committee of the Board of
Directors approved, effective as of August 19, 2019, the grant of
an inducement stock option to purchase 130,000 shares of the
Company’s common stock to Ms. Joseph. The stock option awarded to
Ms. Joseph has an exercise price of $7.27 per share, the closing
price per share of the Company’s common stock on August 19, 2019,
and will vest and become exercisable over four years, with 25% of
the shares vesting on August 19, 2020, the one-year anniversary of
the vesting commencement date, and the remaining shares vesting
ratably over the subsequent 36 months, subject to Ms. Joseph’s
continued service with the Company. The stock option is subject to
acceleration upon a change in control. The stock option has a
ten-year term and is subject to the terms and conditions of the
stock option agreement pursuant to which the option was
granted.
The options were granted as inducements material to Ms. Joseph
entering into employment with the Company in accordance with NASDAQ
Listing Rule 5635(c)(4).
About Millendo Therapeutics, Inc.
Millendo Therapeutics is a late-stage biopharmaceutical company
primarily focused on developing novel treatments for orphan
endocrine diseases where current therapies do not exist or are
insufficient. As a leading orphan endocrine company, Millendo
creates distinct and transformative treatments where there is a
significant unmet medical need. The company is currently advancing
livoletide for the treatment of Prader-Willi syndrome, nevanimibe
for the treatment of classic congenital adrenal hyperplasia and
MLE-301 for the treatment of vasomotor symptoms associated with
menopause. For more information, please visit www.millendo.com.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this communication regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995, known as the PSLRA. These include
statements regarding the transition of the general counsel office
and management’s intentions, plans, beliefs, expectations or
forecasts for the future, and, therefore, you are cautioned not to
place undue reliance on them. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. Millendo undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise, except to the extent required by law.
We use words such as “anticipates,” “believes,” “plans,” “expects,”
“projects,” “future,” “intends,” “may,” “will,” “should,” “could,”
“estimates,” “predicts,” “potential,” “continue,” “guidance,” and
similar expressions to identify these forward-looking statements
that are intended to be covered by the safe-harbor provisions of
the PSLRA. Such forward-looking statements are based on our
expectations and involve risks and uncertainties; consequently,
actual results may differ materially from those expressed or
implied in the statements due to a number of factors, including,
but not limited to, risks related to changes in the composition of
our management team and related transition. New factors emerge from
time to time and it is not possible for us to predict all such
factors, nor can we assess the impact of each such factor on the
business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those
contained in any forward-looking statements. Forward-looking
statements included in this release are based on information
available to Millendo as of the date of this release. Millendo
disclaims any obligation to update such forward-looking statements
to reflect events or circumstances after the date of this release,
except as required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190820005214/en/
Millendo Investor Contact: Stephanie Ascher Stern
Investor Relations 212-362-1200 stephanie.ascher@sternir.com
Millendo Media Contact: Betsy Yates MacDougall
781-235-3094 byates@macbiocom.com
Millendo Therapeutics (NASDAQ:MLND)
Historical Stock Chart
From Mar 2024 to Apr 2024
Millendo Therapeutics (NASDAQ:MLND)
Historical Stock Chart
From Apr 2023 to Apr 2024